The higher incidence of AEs in the TACE-Apatinib group than that in the TACE-Sorafenib group in patients with intermediate or advanced HCC could be associated with the higher activities of Apatinib [36], and the AEs could be associated with the inhibition of VEGF signaling pathway. Here, VEGFA is linked to hepatocellular carcinoma.